Kip1 and p21
INTRODUCTION
Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy that is characterized by the Philadelphia chromosome [1, 2] , a shortened chromosome 22 that is a by-product of a reciprocal chromosomal translocation between the long arms of chromosomes 9 and 22 t (9; 22) (q34; q11), resulting in a chimeric Bcr-Abl oncoprotein with highly deregulated, constitutive tyrosine kinase activity [3, 4] . The most commonly occurring from of Bcr-Abl is a 210-kDa protein that is a critical role in the pathogenesis of CML [5] . Bcr-Abl activates a variety of signaling pathways, including the Ras/Raf-1/MEK/ERK [6] , PI3K/Akt [7] , JAK/STAT [8] , and NF-κB [9] signaling pathways. These signaling pathways play important role in Bcr-Abl-mediated leukemogenesis. The Ras pathway regulates multiple biological aspects including mitogenesis and differentiation [10, 11] , and is constitutively activated in Bcr-Abl transformed cells. Moreover, inhibition of Ras activity represses the oncogenic ability of Bcr-Abl [6] .
Bcr-Abl activates the Ras pathway through the adaptor protein Grb2, which associates with the guanine nucleotide exchange factor Sos and binds to the phosphorylated tyrosine residue 177 within the Bcr region of BcrAbl. Sos forms a platform for recruitment of Ras, resulting in the activation of Ras from GDP-to GTP-bound state [12, 13] . The activated Ras phosphorylates Raf, and ERK is phosphorylated by MEK, which is phosphorylated and activated by the activated Raf-1 [14] . ERK then translocates into the nucleus and promotes cell proliferation through activation of various transcription factors as playing important roles in Bcr-Abl-mediated leukemogenesis [15] . On the other hand, the anti-apoptotic factor # These authors contributed equally. of the Bcl-2 family, Mcl-1, is constitutively expressed in a Ras/Raf-1/MEK-dependent manner via Ras activation in Bcr-Abl positive cells [16] . Moreover, Raf-1 has been reported to have an important role in regulation of cell cycle progression [17] . Thus, in Bcr-Abl expressing cells, Ras pathway plays an important role in both cell proliferation and survival.
Raf kinase inhibitor protein (RKIP), which is a member of the phosphatidylethanolamine binding protein 1 (PEBP1) family, is a ubiquitously expressed and constitutively conserved protein [18] . RKIP inhibits activation of MEK by Raf-1 and its downstream signal transduction, resulting in blocking the MAP kinase pathway [19, 20] . It has been reported that RKIP expression is downregulated in metastatic prostate cancers and the loss of RKIP levels promotes the metastatic potential of prostate cancer cells [21] . Moreover, RKIP has been reported to be downregulated in malignant melanoma [22] , hepatocellular carcinoma [23] , breast cancer [24] , and colorectal cancer [25, 26] . These data suggest RKIP might play as a tumor and/or metastasis suppressor for solid tumors. However, it has been reported that RKIP expression has no relationship with ERK phosphorylation or the clinical course of disease in patients with melanoma or breast cancer [24, 27] . These different observations suggest that RKIP contributes to the regulation of not only MAPK signaling including phosphorylated ERK but also other signal pathways.
In the present study, we investigated the role of RKIP in CML cell lines and the Bcr-Abl + hematopoietic progenitor cells derived from CML patients. We found that Bcr-Abl suppressed the expression of RKIP in CML cells, and detected changes of the cell cycle regulator proteins in CML-derived hematopoietic progenitor cells and CML cell lines. Interestingly, we also found the upregulation of p27
Kip1 and p21 Cip1 through FOXM1 inactivation in RKIP overexpressed-CML cells.
MATERIALS AND METHODS

Reagents
Imatinib mesylate (STI571) and AMN107 were kindly provided by Novartis Pharmaceuticals (Basel, Switzerland). BMS354825 was kindly provided by Bristol-Myers Squibb (New York, NY). Each compound was prepared as a 10 mM stock solution in dimethyl sulfoxide and stored at -20˚C. Experiments were performed with 1000-fold dilutions of the stock solutions into reaction mixtures.
Cells and Cell Cultures
Human CML cell lines, K562 and Meg01, and human acute myeloblastic leukemia (AML) cell lines, U937 and HL60, were purchased from American Type Culture Collection (Manassas, VA). We established SHG3 cells from the bone marrow of a patient with CML (chronic phase), and YRK2 cells from the bone marrow of patient with AML M5b (French-American-British (FAB) classification). These cells were cultured in RPMI 1640 containing 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 g/mL streptomycin, and 200 U/mL penicillin (GIBCO-BRL, Gaithersburg, MD) and maintained in a humidified 5% CO 2 atmosphere at 37˚C.
Bone Marrow Samples
Prior to participation in the study, patients gave informed consent according to the Declaration of Helsinki. Samples of normal bone marrow were obtained from 6 healthy volunteers. Bone marrow was also obtained from 12 patients with CML in the first chronic phase. Mononuclear cells (MNCs) were isolated from bone marrow samples by Ficoll-Hypaque density gradient centrifuga-tion. CML cells were obtained from patients before they began treatment with Abl kinase inhibitors.
Leukemic Blast Cells Purified by ALDH Activity and CD34 Expression from Bone Marrow Derived MNCs
For 2-color staining, MNCs were stained with anti-CD34-phycoerythrin (PE) conjugated antibody (Becton Dickinson, San Jose, CA) and Aldefluor reagent (StemCo Biomedical, Durham, NC) according to the manufacturer's specifications and separated using fluorescence-activated cell sorting (FACS) (Becton Dickinson). Aldefluor substrate (0.625 g/mL) was added to 2 to 7 × 10 6 cells/mL suspended in Aldefluor assay buffer and incubated for 20 to 30 min at 37˚C to allow the conversion of Aldefluor substrate to a fluorescent product that is retained within the cell because of its negative charge. -GGAGGA-AA-TGCCACACTTAGCG-3', antisense 5'-TAGGAC-TTCTTGGGTCTTGGGGTG-3' ; Bcr-Abl, sense 5'-CGA-GCGGCTTCACTCAGA-3', antisense 5'-ACAGCATTC-CGCTGACCAT-3', and GAPDH; sense 5'-GAACGGGA-AGCTCACTGGCATGGC-3', antisense 5'-TGAGGTCC-ACCACCCTGTTGCTG-3'. PCR conditions for RKIP, FOXM1, Bcr-Abl and GAPDH were 28 cycles of denaturation at 96˚C for 30 sec, annealing at 56˚C for 30 sec, and extension at 72˚C for 30 sec. PCR products were electrophoresed in a 1.5% agarose gel containing 500 g/L ethidium bromide and visualized with UV light. In each experiment, RT-PCR was performed in duplicate. The quantitative real-time PCR was performed by using SY-BER-Green dye on an ABI PRISM 7700 Sequence detector (Perkin-Elmer/Applied Biosystems, Foster City, CA).
Plasmid and RNA Interference
The full-length cDNA coding human RKIP and FOXM1 was obtained by RT-PCR from human bone marrow cDNA (BD Biosciences Clontech, Palo Alto, CA) and cloned into the eukaryotic expression vector pcDNA3.1/V5-His (Invitrogen, Carlsbad, CA). Sequences of recombinant RKIP and FOXM1 cDNAs were verified by automated sequencing.
The vectors for RNA interference (RNAi) specific to human RKIP and Bcr-Abl were constructed based on the piGENE PUR hU6 vector (iGENE Therapeutics, Tsukuba, Japan), according to the manufacturer's instructions. We used the following targeting sequences and oligonucleotides: RKIP shRNA; 5'-AAGGTGGCCTC-CTTCCGTAAA-3', Bcr-Abl shRNA #1: sense 5'-GCAGAGUUCAAAAGCCCUUdTdT-3' and antisense 5'-AAGGGCUUUUGAACUCUGCdTdT-3' and Bcr-Abl shRNA #2, sense 5'-AGCAGAGUUCAAAAGCCCUdTdT-3' and antisense 5'-AGGGCUUUUGAACUCUGCUdTdT -3'. A scrambled shRNA sequence was sense 5`-UUGUACGGCAUC AGCGUUAdTdT and antisense 5`-UUACGUGAUGCCGUA CAAdTdT and used as a control. The vector was transfected into cells by using the Lipofectamine 2000 kit (Life Technologies, Gaithersburg, MD), according to the manufacturer's instructions. After 12 h, the same transfection procedure was repeated, and cells were harvested 48 and 72 h after the initial transfection. Transfection efficiency was consistently 50% to 60%, as determined by the RT-PCR measurement of RKIP, FOXM1, and Bcr-Abl mRNA.
Lentivirus Construction and Production
The full-length RKIP, FOXM1, and b3a2 Bcr-Abl cDNA (a kind gift from Dr. J. Y. Wang, University of California, San Diego, CA) was cloned upstream from the internal ribosomal entry site of replication-deficient, self-inactivating lentiviral vector, pRRLsin-IRES-EGFP. The RKIP, FOXM1, and Bcr-Abl-containing vectors were termed LV-RKIP, LV-FOXM1, and LV-Bcr-Abl, respectively, and the control vector was termed LV-Con. All vector particles, pseudotyped with the vesicular stomatitis virus G glycoprotein, were produced using a three-plasmid expression system as previously described [28] . The cell-free supernatants containing virus particles, LV-RKIP, LV-FOX-M1, LV-Bcr-Abl, and LV-Con, were separately concentrated by ultracentrifugation at 28,000 rpm for 2 h at 4˚C in an SW28 rotor. Virus vector stocks were resuspended in complete DMEM and stored at -80˚C. The virus vector titer of pRRLsin-IRES-EGFP was derived on a fluorescence-activated cell sorter (Becton Dickinson) using transfected HeLa cells. To calculate titers, the number of 
Immunoprecipitation and Western Blot Analysis
For immunoprecipitation and immunoblotting, total cell lysates were prepared from the Abl kinase inhibitor treated-, DNA-transfected, and shRNA-transfected-cells. Cell lysates were incubated with the FOXM1, Rb and Abl-specific monoclonal antibody for 1 hour at 4C, washed Protein G agarose beads (sc-2002, Santa Cruz, CA) were added, and incubated overnight at 4C. The immunoprecipitates were washed 3 times in the lysis buffer, and proteins were eluted with the SDS sample loading buffer. Western blot analysis was performed as previously described [28] using the following antibodies: anti-RKIP goat polyclonal antibody (sc-5426, Santa Cruz), anti-FOXM1 rabbit polyclonal antibody (sc-500, Santa Cruz), anti-c-Abl mouse monoclonal antibody (sc-52990, Santa Cruz), anti-KIS rabbit polyclonal antibody (AB-GENT, San Diego, CA), anti-Rb mouse monoclonal antibody (sc-74562, Santa Cruz), anti-phosphotyrosine (pTyr) mouse monoclonal antibody (sc-508, Santa Cruz), anti-p27
Kip1 rabbit polyclonal antibody (sc-527, Santa Cruz), and anti-p21
Cip1 mouse monoclonal antibody (sc-469, Santa Cruz). To assure equal protein loading, similar experiments were performed with a mouse monoclonal anti-Actin antibody (C-4; ICN, Aurora, OH) as an internal control. After being washed in Tris-buffered saline Tween, blots were incubated with horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or anti-goat IgG (Amersham, Arlington Heights, IL) for 1 h and exposed to X-ray film at room temperature. The signal was detected by chemiluminescence with an ECL detection kit (Amersham).
Cell Proliferation and Viability Assay
To assess cell proliferation, cells (1 × 10 4 ) were seeded in 24-well plates and incubated with STI571 (1 M) at 37˚C. Cells were then transfected with RKIP DNA. After 24, 48, and 72 hours incubation, cell proliferation was measured by counting cells using a hemocytometer. To assess cell viability, the numbers of nonviable cells were determined by counting the cells that showed trypan blue uptake in a hemocytometer and reported as the percentage of untreated control cells. Each data point was performed in triplicate, and the results are reported as mean counts  SD.
Cell Cycle Analysis
DNA content analysis was performed using propidium iodide (PI) (Sigma-Aldrich, St. Louis, MO) staining. In brief, cells were transfected with RKIP DNA. Cells were cultured in 2 ml complete medium containing 1 × 10 6 cells at 37˚C. After 7 days incubation, the cells were washed twice with cold PBS, fixed with 70% ethanol overnight before treatment with 100 g/ml RNase A, and then stained with 50 g/ml PI. The relative DNA content per cell was measured by flow cytometry using an Epics Elite flow cytometer (Coulter Immunotech, Marseille, France). The percentage of cells in G1, S, and G2/M phases, was calculated using ModFit program (Becton Dickinson, San Jose, CA).
Colony Forming Cell Assay
+ cells from CML bone marrow cells were treated the Abl kinase inhibitors, or transfected with scrambled shRNA, RKIP shRNA, Bcr-Abl shRNA #1, RKIP DNA and FOXM1 DNA. Human clonogenic progenitor assays were performed by plating purified populations of cells at concentrations ranging from 2 × 10 2 to 7 × 10 2 (ALDH hi /CD34 + ) into methylcellulose media (Methocut H4435). Colonies were enumerated under light microscopy (Zeiss, Muenchen, Germany) following incubation at 37˚C, 5% CO 2 , for 7 to 10 days.
Collection of Progenitor Cells, and QRT-PCR and Western Blot Analysis in the Progenitor Cells
After the colony forming assays, each colony was harvested by glass syringe, pooled, and washed. Immunoprecipitation and western blotting were performed using the interested antibody. An RNeasy system was used to extract total RNA from approximately 2 × 10 4 cells from each colony, and then RT-PCR and QRT-PCR were also performed using RKIP, FOXM1, Bcr-Abl, and GAPDH primers.
Statistical Analysis
Data are representative of at least three experiments with essentially similar results. These results are expressed as the means ± SD from three independent experiments. The means were compared by using the Student's t test. P values less than 0.01 were considered statistically significant.
RESULTS
The Abl kinase Inhibitors Induce RKIP mRNA Expression in CML Cell Lines
RKIP mRNA were constitutively expressed in CML cell lines (K562, Meg01, and SHG3 cells) (Figure 1(a) ) and AML cell lines (U937, HL60, and YRK2 cells) (Figure 1(b) ). In CML cell lines, the expression of RKIP mRNA was inhibited as compared to AML cell lines. Interestingly, we found that the expression of RKIP mRNA increased in the three CML cell lines treated with Abl kinase inhibitors (STI571, AMN107, or BMS35482 5) for 24 h as compared to untreated cells. However, the Abl kinase inhibitors did not affect the RKIP mRNA expression in the AML cell lines, which did not express Bcr-Abl mRNA. On the other hand, in the CML cell lines transfected with Bcr-Abl shRNA #1, the RKIP mRNA expression was significantly increased as compared to control cells. In the AML cell lines transfected with LVBcr-Abl, the RKIP mRNA expression was reduced as compared to control cells.
As shown in Figure 1 (c), RKIP protein was also constitutively expressed in CML cell line (K562, Meg01 and SHG3 cells) and in AML cell line (HL60, U937 and YRK2 cells) (data not shown). The treatment with Abl kinase inhibitors increased the protein levels of RKIP in CML cells. Moreover, the RKIP protein level was increased in K562 and Meg01 cells transfected with BcrAbl shRNA #1. Thus, Abl kinase inhibitors or the knockdown of Bcr-Abl protein induced RKIP protein expression. The expression of RKIP protein in CML cell lines was at a lower level compared to that in AML cell lines. On the other hand, in the AML cell lines, the Abl kinase inhibitors did not affect the levels of RKIP protein (data not shown). The Abl kinase inhibitors and knockdown of Bcr-Abl using shRNA also inhibited the levels of tyrosine phosphorylated Bcr-Abl (p-Bcr-Abl) in CML cells. Thus, Bcr-Abl expression regulates RKIP mRNA and protein expression.
Effects of RKIP Expression on CML Cell Proliferation
RKIP expression was induced by the Abl kinase inhibitors or the knockdown of Bcr-Abl in CML cells. To examine the functional importance of RKIP expression, we transfected K562 cells with RKIP DNA, and assessed the effects of RKIP on CML cell proliferation (Figure  2(a) ). When K562 cells were transfected with RKIP DNA, the cell proliferation was inhibited compared to untreated cells, and the Abl kinase inhibitor (STI571) significantly inhibited the proliferation of untreated K562 cells. The cell viability of K562 cells transfected with RKIP DNA or treated with STI571 was almost similar (Figure 2(b) ). On the other hand, the expression of RKIP mRNA was significantly increased by STI571 treatment (Figure 2(c) ). These results show that the Abl kinase inhibitor induces RKIP mRNA expression, and RKIP plays an important role in the inhibition of CML cell proliferation by the Abl kinase inhibitors.
Next, we examined how RKIP inhibited CML cell proliferation. The analysis of K562 cells at 5 days posttransfection with RKIP DNA indicated an increase in the percentage of cells in G1 and decrease in G2/M and S population. Moreover, no increase in the sub-G1 population of these cells was observed (Figure 2(d) ). These results demonstrate that the overexpression of RKIP induces a block in G1 phase and no significant increase in apoptosis in CML cells. We previously reported that FOXM1 was aberrant expressed and promoted the cell cycle progression in leukemia cells [28] . Moreover, we also found that FOXM1 expression was aberrant expressed in CML cells, and FOXM1 knockdown inhibited CML cell proliferation (data not shown). However, in CML cells, the Abl kinase inhibitors or Bcr-Abl knockdown did not affect the expression of FOXM1 mRNA and protein. Therefore, we examined whether RKIP overexpression reduces the phosphorylation levels of FOXM1 or affects the expression of the cell cycle regulators, such as p27
Kip1 , p21 Cip1 , and KIS in CML cells. In K562 cells transfected with RKIP DNA, protein extracts were isolated posttransfected 5 days, and western blot analysis was performed to measure protein levels of these cell cycle regulators (Figure 2(e) ). The FOXM1 expression was strongly expressed in CML cells. How ever, the overexpression of RKIP significantly reduced the pFOXM1 status and KIS expression compared to untreated cells. In contrast, the levels of p27
Kip1 and p21 Cip1 protein were increased. The similar results were observed in other CML cell lines (Meg01 and YRK2 cells) (data not shown). These results revealed that RKIP inhibited the phosphorylation of FOXM1 or KIS expression, and prevented the cell cycle progression via 27
Kip1 and p21 Cip1 accumulation resulting in G1 cell cycle arrest in CML cells.
RKIP Expression in Primary CML Progenitor Cells
We examined the RKIP mRNA expression in clinical specimens from CML patients. Hematopoietic progenitor cells from bone marrow were obtained by flow cytometry according to ALDH activity using the substrate Aldefluor. + cells from bone marrow cells derived from 6 healthy volunteers and 12 CML patients, and representative data from two normal (#3 and #4) and two CML samples (#10 and #12) are shown in Figures 3(a) and (b -cell populations were 20.5% and 17.4%, respectively (Figure 3(a) ). There were no significant differences in the population rates among 6 normal healthy volunteers. On the other hand, in bone marrow cells derived from CML patients #10 and #12, the populations of ALDH low cells were 89.3% and 91.4%, respectively, and the populations of ALDH hi cells were 4.7% and 2.6%, respectively. Within these ALDH hi cells, the CD 34 + cell populations were 82.6% and 84.1%, and CD34 -cell population were 14.8% and 11.7%, respectively (Figure 3(b) ). There were no significant differences in the population rates among 12 CML specimens. In ALDH Bcr-Abl shRNA #1 or #2, RKIP mRNA was strongly induced compared to untreated cells (Figure 3(c) ). In normal (#3 and #4) ALDH + cells (Figure 5(a) ). When the CML-derived ALDH hi /CD34 + cells were treated with STI 571 or transfected with RKIP DNA, RKIP expression was increased, and the phosphorylation levels of FOXM1 were decreased. Moreover, the phosphorylation levels of Rb were also decreased. We found that the induction of RKIP expression decreased phosphorylated FOXM1 and Rb levels in CML derived ALDH hi /CD34 + cells. These results show that activated Rb inhibited the phosphorylation of FOXM1. Next, we examined whether the FOXM1 overexpression rescued the effects of cell cycle genes essential for G1-S progression, including Skp2, Cdc25B, KIS, p27
Kip1 , and p21 Cip1 by treatment with STI571 in CML derived ALDH hi /CD34 + cells (Figure 5(b) 
DISCUSSION
We investigated the role of RKIP expression on the cell growth inhibition of CML cells and CML-derived progenitor cells. In this study, we demonstrated that Bcr-Abl inhibited the expression of RKIP and promoted the CML cell proliferation through the FOXM1 activation.
The Ras/Raf-1/MEK/ERK signaling pathway is known to be essential for cellular proliferation, differentiation, apoptosis, survival and migration [29, 30] . The deregulation of them leads to various diseases including malignancies [20, 31] and developmental disorders [32] . However, the regulation of Ras/Raf-1/MEK/ERK pathway is very complex and not clearly understood. It has been reported that RKIP binds to Raf-1 and disrupt downstream of MAP kinase pathway [19] , and the overexpression of RKIP can act as a competitive inhibitor MEK [20] . Moreover, RKIP expression has been shown to downregulated in metastatic prostate cancers and the loss RKIP levels was suggested to promotes the metastatic potential of prostate cancer cells [21] , and it has been shown to be a decrease of RKIP expression in malignant melanoma and breast cancer cells [24, 33] , and the absence of RKIP expression in melanoma metastases [22] .
In cell cycle effects, ERK/MAPK-independent functions of Raf kinases have been reported. Raf-1 activates the Cdk25 phosphatase, which results in CDK activation [17] . The activated CDK4/6 and CDK2 inactivated pRb with Cyclin D and Cyclin E, respectively, which results in cell cycle progression from G1/S transition until the entry into mitosis. In the present study, we found that treatment with Abl kinase inhibitors or reduction of BcrAbl induced the expression of RKIP, reduced the phosphorylated FOXM1 in CML cells and Bcr-Abl + progenitor cells from CML patients. Moreover, the overexpression of RKIP in CML cells and Bcr-Abl + progenitor cells inhibited their proliferation through the reduction of the pFOXM1 status. These results demonstrate that RKIP is suppressed by Bcr-Abl and the induction of RK-IP inhibits the CML progenitor cell proliferation.
In this study, we found at the first time that RKIP inhibited the phosphorylation of FOXM1, the central regulator of the cell cycle, resulting in G1 cell cycle arrest via p27
Kip1 and p21 Cip1 accumulation in CML progenitor cells. Expression and phosphorylation of FOXM1 is induced during the G1 phase of the cell cycle, its expression continues during S phase and mitosis [34] . FOXM1 activity is subjected to different levels of regulation [35] . Upon mitogenic stimulation, Cyclin D/Cdk4, 6 and Cyclin E/Cdk2 inactivate phosphorylated-Rb (pRb), allowing the cells to progress to S-phase, but also relieving inhibition of FOX-M1 by pRb. Furthermore, FOXM1 has been shown to regulate transcription of cell cycle genes essential for G1-S and G2-M progression and chromosome stability and segregation, including Nek2, KIF20A, CENP-A, CENP-F, CDc25A, CDc25B, p27 Kip1 , KIS, Cyclin B, and Cyclin D [35] [36] [37] [38] [39] . FOXM1 has been also reported to contribute to oncogenesis in basal cell carcinomas, hepatocellular carcinomas, and primary breast cancer [40, 41] . Moreover, we have been reported that in acute leukemia cell lines, the expression of FOXM1 mRNA was significantly higher than normal progenitor cells [28] . The reduction of FOXM1 expression increased protein expression of p21
Cip1 and p27
Kip1
. In the clinical samples (127AML (M1; 21, M2; 56, M4; 32, M5; 18)), FOXM1 mRNA was overexpressed in all AML specimens (127/127; 100%). The relative folds of FOXM1 gene expression were for AML: 2.14  0.31 (M1), 2.26  0.47 (M2), 1.65  0.42 (M4), and 1.92  0.38 (M5). In ALDH hi /CD34 + progenitor cells derived from AML patients, the colony numbers were remarkably increased by FOXM1 overexpression. FOXM1 is an essential transcription factor for development of acute leukemia cells, and regulate the growth of ALDH hi /CD34 + progenitor cells derived from AML patients. In this study, we also showed that FOXM1 expression in CML cells was increased compared to normal ALDH hi /CD34 + cells. However, the Abl kinase inhibitors or Bcr-Abl knockdown did not affect the expression of FOXM1 mRNA and protein. On the other hand, the overexpression of RKIP or Bcr-Abl knockdown reduced the pFOXM1 status and KIS expression, and induced p27
Kip1 and p21 Cip1 expression resulting in inhibition of CML cells. These results demonstrate that FOXM1 may be one of target proteins for RKIP.
The ALDH hi /CD34 + progenitor cells derived from CML patients were significantly reduced when they were treated with STI571, AMN107, and BMS354825 or transfected with Bcr-Abl shRNA #1. Moreover, the relative ex-pression of RKIP mRNA was increased and the pFOX-M1 status was decreased in the progenitor cells treated with the Abl kinase inhibitors or transfected with Bcr-Abl shRNA #1. In ALDH hi /CD34
+ progenitor cells transfected with RKIP DNA, the colony forming activity was inhibited, and the combination with the Abl kinase inhibitor showed more strong effects. In contrast, in ALDH hi / CD34
+ progenitor cells transfected with RKIP shRNA, the inhibition effects of colony formation activity by the Abl kinase inhibitors were weakened. These results indicate that the expression of RKIP induced by the Abl kinase reduce the pFOXM1 status and colony-forming cells derived from CML progenitor cells. Moreover, the RKIP overexpression decreased the phosphorylation levels of FOXM1 and Rb proteins, promoted the cell cycle progression via reduction Skp2, Cdc25B, and KIS proteins expression and induction of p27
Kip1 and p21 Cip1 expression in CML-derived ALD-H hi /CD34 + progenitor cells. These findings indicate that Bcr-Abl inhibited the expression of RKIP, and reduced the phosphorylated FOXM1, resulting in the promotion of Bcr-Abl + progenitor cell proliferation. This study shows for the first time that Bcr-Abl represses the expression of RKIP and that the Abl kinase inhibitors induced RKIP expression. Moreover, RKIP reduces the pFOXM1 status. These induced RKIP plays an important role in cell growth inhibition in CML progenitor cells in vitro.
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